Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House passes early cancer detection bill

This article was originally published in The Gray Sheet

Executive Summary

On March 27, House passes bill (HR 1132) authorizing $1.25 billion for breast and cervical cancer screening programs between 2008-2012. Introduced by Reps. Tammy Baldwin, D-Wisc., and Sue Myrick, R-N.C., the measure reauthorizes the National Breast and Cervical Cancer Early Detection Program. The bill also changes the target date for achieving reductions in the rate of mortality from breast and cervical cancer from 2000 to 2020. Senate companion legislation (S 624), introduced by Sens. Barbara Mikulski, D-Md., and Kay Hutchison, R-Texas, was approved by the Senate Health, Education, Labor & Pensions Committee on March 15...

You may also be interested in...

Early cancer detection law

President Bush reauthorizes National Breast and Cervical Cancer Early Detection Program as he signs the bill into law April 20. The law authorizes $1.25 billion for breast and cervical cancer screening programs over the 2008-2012 period (1"The Gray Sheet" April 2, 2007, In Brief). During "the span of my administration, we have spent, along with Congress, $6.7 billion" to fund breast and cervical cancer research and prevention, Bush noted...

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts